Astrazeneca (AZN) Stock
Global pharmaceutical company with strong cancer and respiratory portfolio. Here's the price, business snapshot, and what's worth knowing about Astrazeneca in August 2026.
AstraZeneca PLC (AZN) is a large‑cap global biopharmaceutical company focused on discovery, development and commercialisation of prescription medicines, with particular strength in oncology, cardiovascular, renal & metabolic (CVRM), and respiratory therapies. The firm combines a broad marketed portfolio with an active R&D pipeline and significant investment in biologics and precision medicines. For investors, key considerations include steady revenue from established drugs, growth driven by newer oncology and rare‑disease launches, and continued R&D spend that can both support long‑term value and create near‑term earnings variability. The company operates globally, exposing it to different regulatory and pricing environments and currency movements. AstraZeneca has historically paid dividends, but dividend levels and share price can fluctuate with trial outcomes, patent expiries and competition. This summary is educational only — not personalised investment advice — and investors should weigh growth potential against clinical, regulatory and commercial risks.
Why It’s Moving
AstraZeneca’s latest moves reflect a tug-of-war between deal rumors, trial noise, and pipeline confidence
- AstraZeneca’s recent stock swings have been driven by shifting views on the Bristol Myers Squibb merger chatter, with investors first selling off on deal uncertainty and then easing once reports said the talks had been dismissed.
- A late-stage lung cancer trial was halted after a data review, adding a clinical overhang even as the company’s broader oncology pipeline continues to attract attention.
- Analysts have still pointed to AstraZeneca’s resilient earnings and pipeline depth as a buffer, keeping the debate centered on execution rather than a broken growth story.
AstraZeneca’s latest moves reflect a tug-of-war between deal rumors, trial noise, and pipeline confidence
- AstraZeneca’s recent stock swings have been driven by shifting views on the Bristol Myers Squibb merger chatter, with investors first selling off on deal uncertainty and then easing once reports said the talks had been dismissed.
- A late-stage lung cancer trial was halted after a data review, adding a clinical overhang even as the company’s broader oncology pipeline continues to attract attention.
- Analysts have still pointed to AstraZeneca’s resilient earnings and pipeline depth as a buffer, keeping the debate centered on execution rather than a broken growth story.
Sixth Month Growth Performance
next-earnings-question
AZN’s next earnings date is expected on October 30, 2026, based on its established reporting pattern. The release should cover Q3 2026 results, or the nine months ended September 2026. This timing remains an estimate until the company formally confirms the announcement date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AstraZeneca's stock with a target price of $114.08, indicating growth potential.
Financial Health
AstraZeneca is performing well with strong profits, cash flow, and revenue, indicating solid financial health.
Dividend
AstraZeneca's average dividend yield of 1.3% offers some return but may not be appealing for high dividend-seeking investors. If you invested $1000 you would be paid $13 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline drives growth
AstraZeneca’s R&D pipeline, especially in oncology and precision medicines, can support future revenue, though trial outcomes and approvals are uncertain.
Global footprint matters
Wide geographic reach diversifies revenue but brings exposure to regulatory, pricing and currency risks that can affect results.
Innovation and spending
Heavy investment in biologics and new modalities underpins long‑term potential while creating earnings variability in the near term.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
